Impact Of DRGs On Clinical Research Less Than First Feared, Speakers Tell NIH Directors Meeting
In Brief: Calabresi Named DCT Board Chairman; NCI Gets $5 Million Gifts for Intramural Breast Cancer Work
Organ Systems Program Finally Loses a Couple, But Gets OK for Breast Cancer Risk Study RFA
Other Concepts Approves By DCE Board Last Week
New Cancer Education Program “Striking Change,” To Fund CR, Prebaccalaureate, Summer Training
Adamson Rips “Rip Van Bailer”
Trending Stories
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - With five-year cancer survival at an all-time high, does this mean people are living longer?
- Blood Cancer United: A new name at the right moment
- An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”
How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs - In The Headlines: Is early detection always good? Inside NCI’s MCD feasibility trial.
- Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer









